Today the DEA announced that they have a new FDA approved form of THC called Syndros. Syndros is the result of work of Insys Therapeutics to create a new oral THC that has 5mg per ML of solution. – FEDERAL REGISTER LINK –
In the DEA’s findings they are planning to schedule this as a Schedule II drug because.
Dronabinol is a generic name for the (-) delta-9-trans isomer of tetrahydrocannabinol (THC). THC is the primary psychoactive substance in marijuana. Dronabinol is the active pharmaceutical ingredient in Syndros. As stated by HHS, Marinol (synthetic dronabinol in sesame oil and encapsulated in a soft gelatin capsule) was approved by the FDA for medical use on May 31, 1985 and placed in schedule II based on its accepted medical use and high abuse potential. On July 2, 1999, Marinol was rescheduled from schedule II to schedule III because of the findings of the DEA that the difficulty of separating dronabinol from the sesame oil formulation and the delayed onset of behavioral effects due to oral route administration supported a lower abuse potential of Marinol as compared to substances in Schedule II. 64 FR 35928.
Going on to state:
HHS indicated that the formulation of Syndros (oral solution) is easier to abuse than Marinol because this liquid formulation can be manipulated to produce concentrated extracts of dronabinol for abuse by inhalation (smoking or vaping) or through other routes of administration. Because of the large amount of dronabinol in Syndros oral solution it has a greater potential for extraction than Marinol and thus has a greater abuse potential.
Based on the use of Cannabis by the general public DEA feels that this form of THC needs to be a Schedule II drug.
What you find when reading further down is that it appears DEA would rather people smoke it because of the onset of effects are easier to control.
Oral consumption of dronabinol, compared to inhaled THC, may result in psychoactive effects that are delayed and stronger with an increased risk of experiencing serious adverse events.
But then they quickly add:
When dronabinol (THC) is smoked, the drug rapidly reaches the brain and psychoactive effects are felt within minutes of inhalation, which allows the subject to control the dose more readily.
The DEA is full of contradictory things but this just about takes the cake. Using a substance via oral methods pose issues that smoking or inhalation don’t and is better at controlling the dose. However they are afraid that people will do just that. Take this new drug and turn it into something they can control the dose better.
There is a time that this potential rule can be commented on, see the link at the top of the page to the federal register.